Tumor necrosis factor-alpha binding capacity and anti-infliximab antibodies measured by fluid-phase radioimmunoassays as predictors of clinical efficacy of infliximab in Crohn's disease.

Download in:

• JSON
• RDF
• N3/Turtle
• N-Triples

View as

• Triples